Neutropenia: Difference between revisions
Jump to navigation
Jump to search
imported>David E. Volk m (subpages, wikilink) |
imported>Ro Thorpe |
||
| Line 13: | Line 13: | ||
[[Clinical practice guideline]]s define [[fever|febrile]] neutropenia as "a single oral temperature of >=38.3°C (101°F) or a temperature of >=38.0°C (100.4°F) for >= 1 h. Neutropenia is defined as a neutrophil count of <500 cells/mm3, or a count of <1000 cells/mm3 with a predicted decrease to <500 cells/mm3"<ref name="pmid11850858">{{cite journal |author=Hughes WT, Armstrong D, Bodey GP, ''et al'' |title=2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer |journal=Clin. Infect. Dis. |volume=34 |issue=6 |pages=730–51 |year=2002 |pmid=11850858 |doi=|url=http://www.journals.uchicago.edu/CID/journal/issues/v34n6/011605/011605.html}}</ref> | [[Clinical practice guideline]]s define [[fever|febrile]] neutropenia as "a single oral temperature of >=38.3°C (101°F) or a temperature of >=38.0°C (100.4°F) for >= 1 h. Neutropenia is defined as a neutrophil count of <500 cells/mm3, or a count of <1000 cells/mm3 with a predicted decrease to <500 cells/mm3"<ref name="pmid11850858">{{cite journal |author=Hughes WT, Armstrong D, Bodey GP, ''et al'' |title=2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer |journal=Clin. Infect. Dis. |volume=34 |issue=6 |pages=730–51 |year=2002 |pmid=11850858 |doi=|url=http://www.journals.uchicago.edu/CID/journal/issues/v34n6/011605/011605.html}}</ref> | ||
A [[clinical prediction rule]] can estimate the risk of | A [[clinical prediction rule]] can estimate the risk of morbidity in the febrile patient with neutropenia.<ref name="pmid10944139">{{cite journal |author=Klastersky J, Paesmans M, Rubenstein EB, ''et al'' |title=The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients |journal=J. Clin. Oncol. |volume=18 |issue=16 |pages=3038–51 |year=2000 |pmid=10944139 |doi=|url=http://jco.ascopubs.org/cgi/content/full/18/16/3038}} (See [http://jco.ascopubs.org/cgi/content/full/18/16/3038/TBL60416 Table 4] for the prediction rule)</ref> A score of >=21 indicates low risk. | ||
==Prevention== | ==Prevention== | ||
Revision as of 18:24, 14 January 2008
The half-life of a neutrophil is less than one-half of a day. [1]
Diagnosis
Grading
Grading is:[2]
- Grade 1: < 2.0 x 109/L (< 2000/mm3) and > 1.1 x 109/L (> 1500/mm3)
- Grade 2: < 1.5 x 109/L (< 1500/mm3) and > 1.0 x 109/L (> 1000/mm3)
- Grade 3: < 1.0 x 109/L (< 1000/mm3) and > 0.5 x 109/L (> 500/mm3)
- Grade 4: < 0.5 x 109/L (< 500/mm3)
Febrile neutropenia
Clinical practice guidelines define febrile neutropenia as "a single oral temperature of >=38.3°C (101°F) or a temperature of >=38.0°C (100.4°F) for >= 1 h. Neutropenia is defined as a neutrophil count of <500 cells/mm3, or a count of <1000 cells/mm3 with a predicted decrease to <500 cells/mm3"[3]
A clinical prediction rule can estimate the risk of morbidity in the febrile patient with neutropenia.[4] A score of >=21 indicates low risk.
Prevention
Granulocyte colony-stimulating factor is indicated in selected settings.[5][6]
References
- ↑ Carneiro, José; Junqueira, Luiz Carlos Uchôa (2005). Basic histology: text & atlas. New York: McGraw-Hill, Medical Pub. Division. ISBN 0-07-144091-7.
- ↑ Anonymous (1999). Common Toxicity Criteria (CTC). Cancer Therapy Evaluation Program. Retrieved on 2008-01-06.
- ↑ Hughes WT, Armstrong D, Bodey GP, et al (2002). "2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer". Clin. Infect. Dis. 34 (6): 730–51. PMID 11850858. [e]
- ↑ Klastersky J, Paesmans M, Rubenstein EB, et al (2000). "The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients". J. Clin. Oncol. 18 (16): 3038–51. PMID 10944139. [e] (See Table 4 for the prediction rule)
- ↑ Kuderer NM, Dale DC, Crawford J, Lyman GH (2007). "Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review". J. Clin. Oncol. 25 (21): 3158–67. DOI:10.1200/JCO.2006.08.8823. PMID 17634496. Research Blogging. ACP JC Review
- ↑ Frei, Emil; Kufe, Donald W.; Holland, James F. (2003). Cancer medicine 6: Granulocyte colony-stimulating factor. Hamilton, Ont: BC Decker. ISBN 1-55009-213-8. Full text